Lynk Pharmaceuticals Co., Ltd.

Iambic Therapeutics is the latest biopharmaceutical company to raise a venture capital mega-round in support of an artificial intelligence-powered drug discovery platform and emerging clinical-stage

Eikon Therapeutics, Inc. announced the first venture capital mega-round of $100m or more for June, revealing that it raised $106m in the first tranche of a series C funding round on 1 June. The finan

EQRx, Inc. launched in 2020 with a singular goal of developing “me-too” drugs that could get to market faster than generics with dramatically lower prices over competitor brands, lowering costs for p

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly/Innovent Deal Follows FDA’s Rejec